SCHEDULE 13G: Key Investors Divest Entire Stake in ReShape Lifesciences, Reducing Beneficial Ownership Below 5%

Multiple investment entities and Michael Bigger have reported the sale of their entire beneficial ownership in ReShape Lifesciences Inc., reducing their collective stake from nearly 10% to zero as of February 19, 2025.

Summary

• Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, District 2 Capital Fund LP, District 2 Capital LP, District 2 GP LLC, District 2 Holdings LLC, and Michael Bigger (collectively, the "Reporting Persons") filed a Schedule 13G.
• As of February 18, 2025, Bigger Capital Fund L P and District 2 Capital Fund LP each beneficially owned 160,000 shares of ReShape Lifesciences Inc. Common Stock, representing approximately 4.84% of the outstanding shares each.
• Michael Bigger, through his control over the aforementioned entities, was deemed to beneficially own 320,000 shares, representing approximately 9.68% of the outstanding Common Stock as of February 18, 2025.
• The beneficial ownership percentages are based on 3,305,087 shares of Common Stock outstanding, excluding shares underlying warrants, as of the completion of an offering referred to in the Issuer's prospectus filed on February 18, 2025.
• The Reporting Persons also held warrants for an additional 160,000 shares each (320,000 for Michael Bigger), but these warrants are not exercisable as of the filing date and are subject to shareholder approval and a 4.99% beneficial ownership limitation.
• Prior to market open on February 19, 2025, the Reporting Persons sold all of their Common Stock holdings.
• Subsequent to February 18, 2025, all Reporting Persons, including Michael Bigger, reported no beneficial ownership of ReShape Lifesciences Inc. Common Stock, as the warrants are not currently exercisable and are subject to beneficial ownership limitations.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to a significant investor group divesting their entire common stock holdings, which can be perceived as a lack of confidence in the company's future by a major shareholder.

Negatives

• A significant investor group, led by Michael Bigger, has fully divested their common stock holdings in ReShape Lifesciences Inc., reducing their beneficial ownership from nearly 10% to 0%.
• The sale of a substantial stake by a major investor could be perceived negatively by the market, potentially signaling a lack of confidence or a strategic exit.

Risks

• The warrants held by the Reporting Persons are not currently exercisable and are subject to shareholder approval and a 4.99% beneficial ownership limitation, meaning their conversion into common stock is not guaranteed and is capped.

Future Outlook

The document indicates that warrants held by the Reporting Persons are not currently exercisable and their exercise is subject to future shareholder approval and a 4.99% beneficial ownership limitation, implying potential future share issuance if these conditions are met and the warrants are exercised.

Industry Context

This filing is a standard regulatory disclosure of a change in beneficial ownership by an investor group and does not provide direct insights into broader industry trends or competitive landscape for ReShape Lifesciences Inc. It primarily reflects an investment decision by specific entities.

Stakeholder Impact

• Shareholders: The divestment by a significant investor could lead to negative market sentiment and potential share price depreciation.
• Creditors: No direct impact mentioned, but a decline in share price could indirectly affect the company's financial standing and ability to raise future capital.

Next Steps

• Shareholder approval will be required for the exercise of warrants held by the Reporting Persons, which are also subject to a 4.99% beneficial ownership limitation.

Key Dates

Keywords

ReShape Lifesciences Inc., Schedule 13G, Beneficial Ownership, Michael Bigger, Bigger Capital Fund, District 2 Capital, Common Stock, Warrants, SEC Filing, Investor Divestment